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Hereditary angioedema (HAE) is a relatively rare disease,with an estimated prevalence of approximately 1 per
50,000 in the general population. Despite its rarity, HAE has
become an area of intense interest within the medical com-
munity. This interest likely reflects several different aspects
of HAE, including: the high potential for significant morbid-
ity and mortality associated with attacks of angioedema in
HAE patients, the frequent failure to make an accurate and
timely diagnosis, the progress in unraveling the underlying
pathophysiology of HAE, and the tremendous advances in
treatment options. To limit the morbidity and mortality that
has long afflicted patients with HAE, it has become increasingly
important that the clinician understand both the underlying
mechanisms of swelling in HAE and the newer treatment strat-
egies that have been developed for HAE. This supplement
contains 3 reviews that summarize the current state-of-the-art
regarding the pathophysiology and treatment of HAE.
The pathophysiology of HAE is reviewed by Zuraw in
this supplement. The discovery that HAE patients were deficient
in C1 inhibitor (C1INH) quickly led to the subsequent discovery
that the protein could either be nonsecreted (Type I HAE) or
dysfunctional (Type II HAE). These observations led to the
cloning of the gene for C1INH (SERPING1), and the discovery
that HAE ultimately results from a mutation of that gene. Type
II HAE has been found to result almost exclusively from
mutations on the C1INH reactive mobile loop, while Type I
HAE results from mutations scattered throughout the gene.
C1INH inactivates a large number of plasma serine
proteases, including the complement proteases and contact
system proteases. In the absence of sufficient C1INH, these
proteolytic cascades become dysregulated. An elegant series
of experiments demonstrated that bradykinin, generated
through activation of the plasma contact system, is the pri-
mary mediator of swelling in HAE. Once generated, brady-
kinin binds to bradykinin B2 receptors on vascular endothe-
lial cells and increases vascular permeability primarily by
disrupting the tight junctions that normally prevent water
movement through the endothelial layer. Bradykinin catabo-
lism is mediated by several peptidases, and there is evidence
that variation in the level of these peptidases by drugs or
genetic polymorphisms may influence bradykinin actions.
C1INH replacement therapy is reviewed by Frank in
this supplement. Although several antifibrinolytics and ana-
bolic androgen drugs can decrease HAE attack frequency and
severity when administered prophylactically, their efficacy
was not perfect and was further limited by side effects. While
C1INH concentrates have been widely used to treat acute
attacks of HAE for many years, there was limited randomized
trial data to support this and these drugs were not available in
the United States.
Three different C1INH concentrates were recently tested
in double-blind randomized placebo-controlled studies. All 3
concentrates demonstrated significant benefit and excellent
safety when used to treat acute attacks of HAE. A pasteurized
plasma derived C1INH (pdC1INH, Berinert, CSL Behring) 20
U/kg was licensed for use in the treatment of acute attacks in the
United States and is currently in use in Europe. A recombinant
human C1INH (rhC1INH, Rhucin, Pharming) was recently
approved in the European Union for this indication and should
shortly be reviewed by the FDA. Nanofiltered pasteurized
plasma derived C1INH (nf-C1INH, Cinryze, ViroPharma) did
not receive approval for the acute indication in the United States.
The nf-C1INH was also studied in a separate prophylactic trial
and shown to significantly protect HAE patients against attacks
when administered at a dose of 1000 U every 3–4 days. Based
on this, nf-C1INH has been licensed in the United States for
prophylactic use.
In addition to C1INH replacement, drugs targeting
bradykinin generation and actions has been developed and are
reviewed by Riedl in this supplement. A potent and specific
plasma kallikrein inhibitor (ecallantide, Kalbitor, Dyax) was
shown in 2 separate double-blind randomized placebo-con-
trolled studies to be effective in treating acute attacks of
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HAE. Ecallantide is administered by subcutaneous injection
at a dose of 30 mg and is licensed in the United States but not
Europe for treatment of acute attacks.
A separate approach is to antagonize the action of brady-
kinin using a bradykinin B2 receptor antagonist. Icatibant (Fira-
zyr, Shire) is a specific bradykinin B2 receptor antagonist that is
administered by subcutaneous injection at a dose of 30 mg. Two
double-blind randomized placebo-controlled studies assessed
the efficacy of icatibant in the treatment of acute attacks. The
European study successfully demonstrated the efficacy of icati-
bant, and it is now licensed in Europe for the treatment of acute
attacks. The American study, however, failed to meet its primary
end point. As a consequence, an additional trial is currently
underway in the United States.
CONCLUSIONS
Elucidation of the underlying pathophysiology of HAE
directly led to the development of a number of new and
effective drugs to treat this disease. Based on the available
evidence, pdC1INH, nf-C1INH, rhC1INH, ecallantide, and
icatibant all seem to be effective for the treatment of acute
attacks in HAE. In addition, nf-C1INH appears to be effective
for long-term prophylaxis of HAE. Understanding the safety
profile of these drugs will require additional monitoring;
however, all 5 seem to be generally well tolerated.
A key need for the future will be to better define the
advantages and disadvantages of each of these drugs and
develop algorithms to optimize the care of patients with
HAE, both with respect to which patients should receive
prophylactic treatment and which drug to use to treat acute
attacks. HAE disease severity is highly variable, and treat-
ment will need to be optimized based on individual patient
needs. Ultimately, the success of these promising new drugs
will be judged by the extent to which HAE patients can
resume a normal life.
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